Processing of polymetallic sea nodules: An overview

Polymetallic sea nodules are the potential sources of copper, nickel, cobalt and manganese. As the land based resources of these metals are depleting very fast, a considerable R&D effort have been made all over the world to extract the metals from the sea nodules during the past four decades. The paper summarises the processes developed by various R&D organisations and metallurgical consortia for the extraction of metal values from the sea nodules. Since the copper, nickel and cobalt in the sea nodules are in oxide Forms and they associate in the lattices of iron and manganese minerals, for extraction of these metals the lattices are broken either by hydrometallurgical reduction or by reductive pyre-treatment. Based on this criteria, processing methods have been broadly divided into two categories : (i) pyrometallurgical treatment followed by hydrometallurgical processing and (ii) purely hydrometallurgical processing. Processes developed under these two categories have been discussed highlighting their merits and demerits. Pilot plant studies carried out by various metallurgical consortia like Knnecott Copper Corporation, Deep Sea Ventures, Metallurgie Hoboken - Overpelt, International Nickel Company are also given. The R&D efforts made in India in the processing of sea nodules during last one decade and the future programme are also discussed

Processing of dust materials from Indian copper plants

In the pyrometallurgical processing of copper are, there is considerable amount of copper losses in the form of dust from the roaster, smelter and converter. Most of this dust is simply charged back into the smelting cir¬cuit, thereby reducing the capacity offresh charge processing. In the present paper separate processing of copper dust sample by sulphuric acid leaching method has been examined with the idea that the resulting leached cop¬per sulphate solution can be used as electrolyte in the copper electro¬refining section of the plant. The copper dust sample from Khetri Copper Complex, Rajsthan contained about 22% copper. The XRD analysis of the sample revealed that copper was mainly present in the forms of ox¬ides, sulphates and sulphides. Simple water leaching of the dust sample dissolved copper to the tune of 30%. This implied that about 30% of cop¬per was present in the sulphate form and rest of the copper was in the oxide and sulphide forms for which acid leaching process might be suit¬able. Sulphuric acid leaching at various concentration and at varied solid : liquid ratio, time and temperature were carried out at atmospheric pressure. The maximum recovery of copper obtained in these experiments was found to be about 52%. Since the sulphuric acid leaching at atmospheric presssure did not yield good results, the dust sample was leached at higher pressure in an autoclave on 200 g scale and the recovery of copper improved to 80%

Reduction of Emission from Aluminium Industries and Cleaner Technology

Aluminium metal is produced by electrolytic reduction of alumina in cells lined with carbon blocks. During the process of smelting different gaseous emissions like PFC (per flurocarbon).HF PAH (poly aromatic hydrocarbon), CO2, SO„ particulate matters etc. occur in to the atmosphere. The concentration of emission from a cell depends upon the type of cell, bath chemistry, scrubbing system and gas cleaning equipment used. These emissions cause severe environmental damages such as global warming and disease like fluorosis, cancer, asthma, emphysema, bronchitis etc. Through the development of newer technologies like, intro-duction of prebake technology, use of non-consumable (inert) anode, use of computer controlled and point feeding of alumina to the cell to control the frequency and duration of anode effects, use of low carbon pitch to replace tar, use of pollution monitoring and control equipment etc., there is a significant reduction in the emission levels. This paper deals with the factors infl-uencing the generation of these emissions and its reduction through the development of various cleaner technologies. Use of pollution control equipment and other remedial mea-sures to minimise the environmental pollution are also discussed

Hepatoprotective activity of ethanol extract of Pavetta Indica Linn leaves

Background: Traditionally, the bark of Pavetta Indica Linn., in decoction or pulverized, is administered, especially to children, to correct visceral obstructions. The decocted leaves are used externally to alleviate the pains caused by hemorrhoids. The root, pulverized and mixed with the ginger and rice-water, is given in dropsy. A local fomentation with the leaves is useful in relieving the pain of piles. Paracetamol (PCM) toxicity generates free radicals and raised serum enzyme levels-SGPT, SGOT, Alkaline Phosphatase and S. Albumin. It causes necrosis, congested vessels, multifocal area of fatty changes nuclear disintegration, sinusoidal dilation, kuffer cell hyperplasia. The reverse is considered as the index of hepatoprotective activity. The present study is being taken up to screen hepatoprotective action of P. Indica Linn.Methods: The acute liver damage in albino rats was induced by per oral administration of a single dose of 2000mg/kg b.w. PCM suspension in 0.5% Carboxy methyl cellulose (CMC) and chronic liver damage by giving the same dose of PCM on the 7th day. The hepatoprotective activity was monitored biochemically by estimating S. transaminase, S. bilirubin and S. Protein on the 8th day of experiment.Results: Ethanol extract of P. Indica inhibited PCM induced liver toxicity in albino rats at 100mg/kg and 200mg/kg b.w as assessed by the biochemical values.Conclusions: Ethanol extract of “P. Indica” exhibited significant hepatoprotective activity

Role of impurities in solvent extraction-electrowinning of copper and nickel for the processing of sea nodules

During the leaching of roasted nodules from Indian Ocean the soluble amine species of iron, manganese and zinc along with valuable metals such as Cu, Ni and Co enter the ammoniacal solution. Even after the purification step, the metal impurities in small amounts remained in the leach solution. In metal separation using LIX 64N, iron and manganese found their way in the nickel and copper electrolytes. Depending on the feed pH of the nickel spent electrolyte, the selective nickel stripping could be achieved with minimum contamination of copper. A flow sheet based on co-extraction-selective stripping has been developed to process the ammoniacal leach liquor of Indian Ocean nodules. While running the continuous SX-EW circuit, the build-up of metallics (Fe and Mn) and organic impurities in the nickel electrolyte was observed which affected the deposition. The cut-off impurity level in electrolyte for nickel winning was determined as : 0.175 Kg/m(3) Mn, 0.010 Kg/m(3) Fe and 20 ppm organic reagent. A purification scheme for nickel bleed stream was developed to recycle the electrolyte back to SE-EW circuit. Copper being a more noble metal than nickel can usually tolerate higher level of impurities. Organic levels of less than 100 ppm in the copper electrolyte produced good sheet deposit. The results showed the possibility of producing electrolytic grade copper and nickel metals of 99.94% and 99.8% purity

Processing of Tungsten Alloy Scrap for the Recovery of Tungsten Metal

Penetrators usedfordefence purposes are prepared by po wder metallurgical technique. The material contains 90% tungsten along with other minor constituents such as iron, nickel, cobalt, chromium, aluminium etc. During the manufacturing process, three forms of scraps are generated whichare, powder, turnings and defective solid. Since the major constituents of the scrap is the costly tungsten metal, attempts were made to recover the metal by four different methods which are described in this paper. Electro-leaching of turnings in a diaphragm cell using chloride electrolyte bath was tried to remove minor elements. The purity of tungsten achieved in thisprocess was 99.9%. In the soda roasting - leaching process of powderliurning scraps, sodium tungstate of 99.85% purity was obtained with 90% yield. Attempt was also made to remove the impurities by acid leaching. 99.8% pure tungsten with 99% yield was achieved by acid leaching. Fine gravity separation and high intensity magnetic separation techniques were also adopted to enhance the tungsten value from the powder scrap, which produced the concentrate containing 96.2% tungsten

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.

BACKGROUND: Studies evaluating titration of antihypertensive medication using self-monitoring give contradictory findings and the precise place of telemonitoring over self-monitoring alone is unclear. The TASMINH4 trial aimed to assess the efficacy of self-monitored blood pressure, with or without telemonitoring, for antihypertensive titration in primary care, compared with usual care. METHODS: This study was a parallel randomised controlled trial done in 142 general practices in the UK, and included hypertensive patients older than 35 years, with blood pressure higher than 140/90 mm Hg, who were willing to self-monitor their blood pressure. Patients were randomly assigned (1:1:1) to self-monitoring blood pressure (self-montoring group), to self-monitoring blood pressure with telemonitoring (telemonitoring group), or to usual care (clinic blood pressure; usual care group). Randomisation was by a secure web-based system. Neither participants nor investigators were masked to group assignment. The primary outcome was clinic measured systolic blood pressure at 12 months from randomisation. Primary analysis was of available cases. The trial is registered with ISRCTN, number ISRCTN 83571366. FINDINGS: 1182 participants were randomly assigned to the self-monitoring group (n=395), the telemonitoring group (n=393), or the usual care group (n=394), of whom 1003 (85%) were included in the primary analysis. After 12 months, systolic blood pressure was lower in both intervention groups compared with usual care (self-monitoring, 137·0 [SD 16·7] mm Hg and telemonitoring, 136·0 [16·1] mm Hg vs usual care, 140·4 [16·5]; adjusted mean differences vs usual care: self-monitoring alone, -3·5 mm Hg [95% CI -5·8 to -1·2]; telemonitoring, -4·7 mm Hg [-7·0 to -2·4]). No difference between the self-monitoring and telemonitoring groups was recorded (adjusted mean difference -1·2 mm Hg [95% CI -3·5 to 1·2]). Results were similar in sensitivity analyses including multiple imputation. Adverse events were similar between all three groups. INTERPRETATION: Self-monitoring, with or without telemonitoring, when used by general practitioners to titrate antihypertensive medication in individuals with poorly controlled blood pressure, leads to significantly lower blood pressure than titration guided by clinic readings. With most general practitioners and many patients using self-monitoring, it could become the cornerstone of hypertension management in primary care. FUNDING: National Institute for Health Research via Programme Grant for Applied Health Research (RP-PG-1209-10051), Professorship to RJM (NIHR-RP-R2-12-015), Oxford Collaboration for Leadership in Applied Health Research and Care, and Omron Healthcare UK